NFORMATION DISCLOSORED ATTY. DOCKET NO.	SERIAL NO.
CITATION 604-781	10/584,470
MAR 1 7 2000 CHIBBER	
A PENG DATE	GROUP
June 22, 2006	1623

EXAMINER			I.S. PATENT DOCUMENTS					FILING DA	
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLA	SS,	SUBCL	ASS IF	APPROPE	RIA
	6,787,151	09/2004	Meijer et al	***********		-	_		
	5,104,856	04/1992	Esko et al	+	_	_			
	5,360,733	11/1994	Fukuda et al	$\perp$	_		_		_
	5,461,143	10/1995	Wong et al	$\perp$		-			_
	5,486,510	01/1996	Bouic et al	$\perp$					_
	5,589,182	12/1996	Tashiro et al	$\perp$					
	5,624,832	04/1997	Fukuda et al						
	5,658,778	08/1997	· Fukuda et al						
	5,843,707	12/1998	Larsen et al						
	5,880,091	03/1999	Cummings et al						
	5,886,029	03/1999	Dhaliwal						
	5,952,393	09/1999	Sorkin, Jr.						
	5,958,770	09/1999	Cham et al						
	5,965,449	10/1999	Novak						
	5,985,936	11/1999	Novak						
	6,042,834	03/2000	Baraka						
	6,087,353	07/2000	Stewart et al						
	6,197,832	03/2001	Sorkin, Jr.						
	6,346,267	02/2002	Fry et al						
	6,383,514	05/2002	Weitkemper et al						
	6,407,085	06/2002	Kief						_
	6,635,461	10/2003	Schwientek et al						
	6,933,291	08/2005	Qi et al						
	6,998,501	02/2006	Wright et al						
	2004/0038923	02/2004	Marth et al						_
	2004/0203111	10/2004	Schwientek et al						_
	2002/0018811	02/2002	Penteado et al						
	2002/0098563	07/2002	Korczak et al						
	2002/0156051	10/2002	Kutney et al						_
	2003/0096316	05/2003	Wester						
	2004/0033521	02/2004	Korczak et al						
	2004/0049352	03/2004	Andre et al						
	2004/0220115	11/2004	Cham						_
	2006/0052351	03/2006	Platt et al						_
-	2007/0254847	11/2007	Liu et al						_
	2002/0183294	12/2002	Barraclough et al						_
	2002/0193317	12/2002	Xia et al						_
	2003/0004147	01/2003	Barraclough et al	$\top$					_
	2004/0249138	12/2004	Lawson			$\vdash$	$\neg$ †		_
	2007/0254847	11/2007	Liu et al				-		_

Examiner: Initial if reference considered, whether or not citation is in conformance with this form with next communication to applicant.

NFORMATION DISCLOSURE	ATTY, DOCKET NO.	SERIAL NO.	
CITATION	604-781	10/584,470	
	APPLICANT		
	CHIBBER		
(Use several sheets if necessary)	FILING DATE	TC/A.U.	
	June 22, 2006	1623	

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	IOITA_ ON
Т	2 335 436	08/2001	Canada	T		1	
十	1237583A	12/1999	China	1	-	ABSTR	Х
H	1243129A	02/2000	· China			ABSTR	X
+	1361111A	07/2002	China	++	<del>                                     </del>	ABSTR	х
+	0 850 243 B1	10/2003	EP	+			
+	1 316 608 A1	06/2003	EP				
t	2 027 434 C1	01/1995	RU	-		×	
H	WO 00/52029 A1	09/2000	PCT	+			
t	WO 00/78789 A1	12/2000	PCT				
+	* WO 02/87548	11/2001	PCT	+			
+	WO 02/24212 A1	03/2002	PCT		1		
+	WO 01/83717 A2	11/2001	PCT	++			
+	WO 02/069980 A2	09/2002	PCT	++			
t	WO 03/075931 A1	09/2003	PCT	+		<b></b>	
t	WO 2004/002497 A1	01/2004	PCT	+			
+	WO 2004/111196 A2	12/2004	PCT	+	<del>                                     </del>		
+	WO 2004/029068 A1	04/2004	PCT				
t	WO 2004/048938 A2	06/2004	PCT	+			
t	WO 98/06405 A1	02/1998	PCT	+		<b></b>	
+	WO 99/39715 A1	08/1999	PCT	+			
t	WO 99/53925 A1	10/1999	PCT	+			
+	WO 97/06176 A2	02/1997	PCT		-		
_			cluding Author, Title, Date, Pertinen	pages.	tc.)		
Т			wres of fur ostanol saponins (48 pgs).	F-9/			
			m patients with acute multiple sclerosis dis lectin glycoprotein ligand-1", Blood, Vol. 1				eness
	GLcNAc-T and Adheren	ice of Huma	'Tumor Necrosis Factor-α in Diabetic Plasr n Leukocytes to Retinal Endothelial Cells'';	Diabetes,	Vol. 53, 296	3-2976 (20	
	Leukemia: Increase in O	-Glycan Cor	s of O-Glycans in Leukocytes from Normal e 2 UDP-GlcNAc:Galβ1-3GalNAc-R (G1c ukemic Cells"; Cancer Research; 51, 1257-	NAc to Ga	lNAc) βl(1-6		
	Buerke, Michael, et al; J. Clin. Invest.; Vol. 93,		sx- Containing Oligosaccharide Attenuates 1994).	Myocardia	Reperfusion	Injury in	Cats"
T	Beum, P.V. and Cheng, Immunology of Complex		synthesis and Function of β1,6 Branched M	ucin-Type	Glycans"; Th	e Molecui	ar

*Examiner			Date Considered		
Examiner: Initial if r	eference considered, whether or not citation is in conformance with	MPEP 6	609; Draw line through citat	ion if not in conformance and not considered.	Include

/Patrick Lewis/ (01/11/2010)

Sheet 3	of 4					
INFORM	ATION DISCLOSURE	ATTY. DOCKET NO.	SE	RIAL NO.		
CITATION		604-781	10	0/584,470		
		APPLICANT				
		CHIBBER				
(Use several sheets if necessary)		FILING DATE	тс	C/A.U.		
		June 22, 2006	June 22, 2006 1623			
	Adenocarcinoma Cell Line'	'; Am. J. Respir. Cell Mo	l. Biol.; Vol. 29, 48-56 (20			
	Chem.; 280(29); 26965-73;	Epub (2005).		Attached to Collagen Type XVIII"; J. Biol		
*	Davies, Michael J., et al; "Atherosclerosis", Journal of			Vcam-1, Pecam, and E-Selectin in Human		
		Forum Section; Core 2 (		olylactosamine expression in O-glycans",		
	Dube, Danielle H. et al, "G Reviews, Vol. 4, No. 6, 477		lammation - Potential for	Therapeutics and Diagnostics", Nature		
		n of Metastasis-Suppressive Gene Nm23-H1 on Glycosy-transferases Involved in the tigens"; J. Cell. Biochem.; 94:1248—1257 (2005).				
	Fox, R.I., et al; "A Novel C	ell Surface Antigen (T305) Found in Increased Fequency on Acute Leukemia Cells and in "; J. Immunol. Vol. 131, No. 2, 761-767 (1983).				
		e Members of the Selecti	lectin Receptor Family Recognize a Common Carbohydrate Epitope, the			
	Fugang P. et al.; "Post Tra	nslational Modifications of Recombinant P-selectin Glycoprotein Ligand-1 Required for "; J. Biol. Chem.; Vol. 271, No. 6, 3255-3264 (1996).				
	Fujita, M. et al; "Pulmonar expression"; J. Applied Phy			ssociated with decreased VEGF gene		
	Goss, P. E. et al; "Inhibitor: 1, 935-944 (1995).	s of Carbohydrate Proces	sing: A New Class of Ant	icancer Agents <sup>1,2</sup> ; Clin. Cancer Res.; Vol.		
	Maaheimo, Hannu et al, "S' adhesion"; Eur J. Biochem;		lyl Lewis x O-glycan, a po	tent inhibitor of lymphocyte-endothelium		
				and High Endothelial Venule-restricted ; Vol. 279, No. 4, 3058-3067 (2004).		
•	Ke, Hu et al; "The Cytotoxi	city of Methyl Protoneo	gracillin (NSC-698793) ar	d Gracillin (NSC-698787), Two Steroidal uman Cancer Cells in vitro"; Phytother.		
		nant Soluble Form of PS n; 99, 1363-1369 (1999)	GL-1 Accelerates Thromb	olysis and Prevents reocclusion in a		
				ed novel core 2-like branched structure ecobiology, Vol. 8, No. 7; 707-717 (1998).		
				ction"; Circ Res.; 96; 925-926 (2005).		
	Kamisako, Toshinori et al, the rats: effects of diosgenir			ciated with abcg5 and abcg8 expressions in 348-352 (2003).		
				systemic lupus erythematosus"; Lupus, 14		
	Vol. 280, No. 7, 5378-5390	(2005.)		electin, and E-selectin"; J. Biol. Chem.,		
				ltransferase Selectively Contributes to P- ology, 174: 4051-4059 (2005).		
		R.J.; "Biochemical Effec		ial of Tunicamycin in Murine L1210		
Examiner	/Patrick Lewis/ (01		Date Considered			

Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SR/08a

s

\*Examiner

heet 4	4 of	f 4		
INFORMATION DISCLOSURE CITATION		ON DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.
			604-781	10/584,470
			APPLICANT	
			CHIBBER	
(Use several sheets if necessary)		I sheets if necessary)	FILING DATE	TC/A.U.
		,,		
			June 22, 2006	1623
	Si		l in Human Pre-B Lymphocytic	β1-6-N-acetylglucosaminyltransferase, Regulates Cell Surfac Leukemia Cell Line KM3 Treated with Phorbolester"; J. Bio
_	N <sub>i</sub>		Specific Induction of E-Selection	in Glomeruli is Augmented following Diabetes mellitus";
		kada, S. et al; "Intercelli abetes"; Diabetes; 52:25		cient Mice are Resistant Against Renal Injury After Induction
	Ro	ccio L. et al; "Molecula bles for P-Selectin Glyco 002).	r Mechanisms Involved in Lym protein Ligand-1 and Heterotri	phocyte Recruitment in Inflamed Brain Microvessels: Critical meric G <sub>r</sub> -Linked Receptors <sup>1</sup> "; <i>J. Immunol.</i> ; 168: 1940–1949
				rol?", QJ Med; 95, 397-403 (2002).
		oss, Russell; "Atheroscle 6 (1999).	rosis - An Inflammatory Disea	e", The New England Journal of Medicine, Vol. 340, 2, 115-
			nda A. Cattle, "Sialyl Ligands to ournal of Neuroimmunology, 4	acilitate lymphocyte accumulation during inflammation of the ; 123-130 (1992).
	I M	edicine; Vol. 8, No. 11;	1211-1217 (2002).	sterolemia and inflammation as partners in crime"; Nature
		einman, Lawrence; "Blo rug Discovery, Vol. 4, 5		Therapy for Multiple Sclerosis: Natalizumab"; Nature Review.
	Bo			uid Phospholipase A2 by Dioscin"; Arch. Pharm. Res.; Vol. 1
	U	brich, Holger, et al; "Le		hesion molecules as targets for therapeutic interventions in tes, Vol. 24, No. 12; 640-647 (2003).
	W	illiams, D. et al; "Mucir	Synthesis II. Substrate Specific	ity and Product Identification Studies on Canine Submaxillar
		and UDP-G1cNAc:Galf b. 23; 1253-1261 (1980)		ac) β6-N-acetylglucosaminyltransferase"; J. Biol. Chem.; 255
	Yo			s Cell Metaplasia in Mouse Lung"; Am. J. Respir. Cell Mol.

/Patrick Lewis/ (01/11/2010) Date Considered

Yu, Jing et al, "Progress in studies on chemical constituents and pharmacological effect of Trigonella foenum-graecum";

Zak, I., et al; "Selectin Glycoprotein Ligands"; Acta Biochemica Polonica; Vol. 47, No. 2; 393-412 (2000).

Chinese Traditional and Herbal Drugs, Vol. 34, (12) 1146-1149 (2003).

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.